Thursday - May 22, 2025
U.S. FDA Oncologic Drugs Advisory Committee votes in favor of the benefit-risk profile of DARZALEX FASPRO(r) (daratumumab and hyaluronidase-fihj) for high-risk smoldering multiple myeloma
May 20, 2025
NEW BRUNSWICK, New Jersey, May 20 [Category: BizHealth & Beauty] -- Johnson and Johnson posted the following news release:

* * *

U.S. FDA Oncologic Drugs Advisory Committee votes in favor of the benefit-risk profile of DARZALEX FASPRO(r) (daratumumab and hyaluronidase-fihj) for high-risk smoldering multiple myeloma

RARITAN, N.J., May 20, 2025 - Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Com . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products